Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials

Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials

Summary: Background: The COVID-19 pandemic highlights the need for therapies that improve immune function in older adults, including interferon (IFN)-induced antiviral immunity that declines with age. In a previous phase 2a trial, RTB101 (previously known as BEZ235), an oral mechanistic target of r...

Full description

Bibliographic Details
Main Authors: Joan B Mannick, MD, Grace Teo, PhD, Patti Bernardo, PhD, Dean Quinn, MD, Kerry Russell, MD, Lloyd Klickstein, MD, William Marshall, MD, Sarb Shergill, PhD
Format: Article
Language:English
Published: Elsevier 2021-05-01
Series:The Lancet. Healthy Longevity
Online Access:http://www.sciencedirect.com/science/article/pii/S2666756821000623

Similar Items

Similar Items